Publikationen aus der Dermatoonkologie

Baker DJ, Frommer L, Uslu U, Engel NW, Zhu D, Kim SI, Sun L, Patel K, Roselle C, Rommel P, Young RM, Epstein JA, Hayat S, Arany Z, June CH. 
AI-driven discovery of GPNMB CAR T cells as a pan-cancer therapy.
Cell 2026; 189(13): 3871-3882.e12. 
doi: 10.1016/j.cell.2026.06.002.

Kleiss MA, Goebeler M, Gesierich A, Uslu U, Goller S.
Rapid regression of a mucosal melanoma after a single dose of immune checkpoint inhibitors.
Eur J Dermatol 2026;36(2):208-210.
https://doi.org/10.1684/ejd.2026.5067 

Goller S, Kleiss MA, Goebeler M, Gesierich A, Uslu U.
Früherkennung des malignen Melanoms [Early Detection of Melanoma].
MMW Fortschr Med 2026;168(9):38-41.
https://doi.org/10.1007/s15006-026-5844-8 

Uslu, U. 
Wer ist ... Ugur Uslu?
Fokus Onkol 2026;29(63).
https://doi.org/10.1007/s15015-026-4567-0 

Liv T, Touze A, Schrama D, Guyetant S, Samimi M, Tetzlaff MT, Wood BA, Harms PW, Kervarrec T. 
RB1 inactivation in cutaneous carcinomas.
Histopathology 2026; 88: 769-789
https://doi.org/10.1111/his.70056

Paudel R, Goller S, Schwarz S, Meder K, Goebeler M, Schmidt M.
AXL is a novel ERK5/KLF4 target in MEK inhibitor-treated melanoma.
Neoplasia 2026;76:101301.
https://doi.org/10.1016/j.neo.2026.101301 

Goller S, Briones LJ, Sánchez BR, Ferreira CS, Piqueras PG.
Journal Club: Current state of neoadjuvant therapy for melanoma.
Eur J Dermatol 2026;36(1):76-80.
https://doi.org/10.1684/ejd.2026.5042 

Goller S, Dege T, Schummer P, Haug L, Meir M, Gehrke T, Klein D, Goebeler M, Kneitz H, Schilling B, Gesierich A, Glutsch V.
Perioperative Pembrolizumab in Locally Advanced Melanoma: A Real-world Single-centre Retrospective Study.
Acta Derm Venereol 2026;106:0009.
https://doi.org/10.2340/actadv.v106.adv-2025-0009 

Cesarato N, Kumar S, Wehner M, Aldisi R, Thiele H, Hamm H, Betz RC.
From Hypotrichosis to Frontonasal Dysplasia: Expanding the Phenotypic Spectrum of ALX4 Variants.
Am J Med Genet A 2026
doi: 10.1002/ajmg.a.70249

Wobser M, Rosenwald A, Eisele F, Maurus K, Topp M, Duell J.
Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma.
Leuk Lymphoma. 2026;67(9):1990-1993.
doi: 10.1080/10428194.2026.2672106.

Saksena A, Siewert C, Turakulov R, Singh O, Abdullaev Z, Zhou T, Karrs J, Alves De Castro JV, Riley D, Skarshaug S, Zgonc V, Sultanaeva L, Teng R, Xi L, Kreitman RJ, von Deimling A, Duran-Ferrer M, Martín-Subero JI, Campo E, Englert B, Richter J, Klapper W, Anagnostopoulos I, Rosenwald A, Wobser M, Fend F, Quintanilla-Martinez L, Ferrer G, Esteller M, Piris MA, Hummel M, Pittaluga S, Raffeld M, Jaffe ES, Capper D, Aldape K.
DNA methylation-based classification of hematolymphoid neoplasms.
Blood Adv. 2026;10(13):4842-4859.
doi: 10.1182/bloodadvances.2024015275.

Dobos G, Jonak C, Klespe KC, Wobser M, de Masson A, Hoffmann J, Mitteldorf C.
Management of Mycosis Fungoides With Chlormethine Hydrochloride Gel in Combination With Systemic Therapies: A Case Series.
Case Rep Dermatol Med. 2026;2026:8813008.
doi: 10.1155/crdm/8813008.

Stadler R, Quaglino P, Woei-A-Jin FJSH, Dummer R, Mitteldorf C, Papadavid E, Ortiz Romero PL, Guenova E, Abe R, Cowan R, Bagot M, Dalle S, Fujimura T, Gambichler T, Morris S, Wehkamp U, Terheyden P, Cozzio A, Dippel E, Alberti-Violetti S, Romejko-Jarosinska J, Wozniacka A, González Barca E, Pujol Vallverdu R, Ramelyte E, Bechter O, Suzuki K, Knobler R, Danhauser-Riedl S, Scarisbrick J; RESMAIN Investigators.
Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet Haematol. 2026;13(2):e98-e109.
doi: 10.1016/S2352-3026(25)00322-9.

Wobser M.
Haematopoietic stem cell transplantation for cutaneous T-cell lymphomas: Decision-guiding prognostic determinants yet to be clarified.
J Eur Acad Dermatol Venereol. 2026;40(1):23-24.
doi: 10.1111/jdv.70174.

Schummer P, Glatzel C, Schrüfer P, Lawrenz I, Dobos G, Wehkamp U, Hüning S, Stranzenbach R, Nicolay JP, Goebeler M, Wobser M.
Brentuximab vedotin and radiotherapy for CD30-positive cutaneous T-cell lymphoma - a retrospective multicenter analysis.
J Dtsch Dermatol Ges. 2026;24(4):495-502.
doi: 10.1111/ddg.15897.

Bernhardt M, Rech A,  Berthold M,  Lappe M, Herbel JN,  Erhard F,  Paschen A, Schilling B,  Schlosser A.
SILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor sensitive and resistant melanoma cells.
Front Immunol 2025; 15:1490821.
DOI: 10.3389/fimmu.2024.1490821

Paudel R,  Goller S,  Deutzmann F, Gillitzer A,  Meder K,  Knorz A, Schrama D,  Goebeler M,  Schmidt M.
MEK5/ERK5 inhibition sensitizes NRAS-mutant melanoma to MAPK-targeted therapy by preventing Cyclin D/CDK4-mediated G1/S progression.
Cell Death Dis 2025; 16(1): 689.
DOI: 10.1038/s41419-025-08036-7

Garcia-Olazabal M, Adolfi MC,  Wilde B,  Hufnagel A, Paudel R,  Lu Y,  Meierjohann S,  Rosenthal GG, Schartl M.
Functional test of a naturally occurred tumor modifier gene provides insights to melanoma development.
G3 (Bethesda) 2025; 15(2): jkae298
DOI: 10.1093/g3journal/jkae298

Chanda T, Haggenmueller S,  Bucher TC,  Holland-Letz T,  Kittler H, Tschandl P,  Heppt MV,  Berking C, Utikal JS,  Schilling B,  Buerger C, Navarrete-Dechent C,  Goebeler M,  Kather JN,  Schneider CV, Durani B,  Durani H,  Jansen M, Wacker J,  Wacker J,  Reader Study Consortium ,  Brinker TJ.
Dermatologist-like explainable AI enhances melanoma diagnosis accuracy: eye-tracking study.
Nat Commun 2025; 16(1): 4739
DOI: 10.1038/s41467-025-59532-5

Haggenmüller S, Wies C,  Abels J,  Winterstein JT,  Heinlein L, Nogueira Garcia C,  Utikal JS,  Wohlfeil SA,  Meier F, Hobelsberger S,  Gellrich FF,  Sergon M, Hauschild A,  French LE,  Heinzerling L,  Schlager JG, Ghoreschi K,  Schlaak M,  Hilke FJ, Poch G,  Korsing S,  Sarfert C, Berking C,  Heppt MV,  Erdmann M, Haferkamp S,  Drexler K,  Schadendorf D,  Sondermann W, Goebeler M,  Schilling B,  Kather JN, Fröhling S,  Llamas-Velasco M,  Requena LC,  Ferrara G, Fernandez-Figueras M,  Fraitag S,  Müller CSL, Starz H,  Kutzner H,  Barnhill R, Carr R,  Resnik KS,  Braun SA, Holland-Letz T,  Brinker TJ.
Discordance, accuracy and reproducibility study of pathologists' diagnosis of melanoma and melanocytic tumors.
Nat Commun 2025; 16(1): 789
DOI: 10.1038/s41467-025-56160-x

Reitmajer M,  Livingstone E,  Heinzerling L,  Thoms KM, Meiss F,  Heppt MV,  Gesierich A, Drexler K,  Meier F,  Schlaak M, Forschner A,  Zimmer L.
Real-world management of adjuvant systemic melanoma therapy: Multi-center survey of 51 DeCOG skin cancer centers.
J Dtsch Dermatol Ges 2025; 24(7):916-926.
DOI: 10.1111/ddg.15963

Reinhard S,  Utikal JS,  Zaremba A, Lodde G,  von Wasielewski I,  Klespe KC, Meier F,  Haferkamp S,  Kähler KC, Herbst R,  Gebhardt C,  Sindrilaru A, Dippel E,  Angela Y,  Mohr P, Pfoehler C,  Forschner A,  Kaatz M, Schell B,  Gesierich A,  Loquai C, Hassel JC,  Ulrich J,  Meiss F, Schley G,  Heinzerling LM,  Sachse M, Welzel J,  Weishaupt C,  Sunderkötter C,  Michl C, Lindhof HH,  Kreuter A,  Heppt MV, Wenk S,  Mauch C,  Berking C, Nedwed AS,  Gutzmer R,  Leiter U, Schadendorf D,  Ugurel S,  Weichenthal M,  Haist M, Fleischer MI,  Lang B,  Grabbe S, Stege H.
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG.
Eur J Cancer 2025; 220:115356
DOI: 10.1016/j.ejca.2025.115356

Forschner A, Kähler KC,  Gschnell M,  Langan EA, Weishaupt C,  Meiss F,  Thoms KM, Wahl RU,  Göppner D,  Garzarolli M, Sachse M,  Schlaak M,  Reitmajer M, Kellner I,  Gesierich A,  Mohr P, Meier F,  von Wasielewski I,  Herbst R, Utikal J,  Pföhler C,  Ulrich J, Terheyden P,  Kaatz M,  Haferkamp S, Leiter U,  Ugurel S,  Weichenthal M,  Berking C, Gutzmer R,  Schadendorf D,  Nanz L, Loquai C.
Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg.
Front Immunol 2025; 16: 1509886.
DOI: 10.3389/fimmu.2025.1509886

Zager JS,  Orloff M,  Ferrucci PF, Choi J,  Eschelman DJ,  Glazer ES, Ejaz A,  Richtig E,  Ochsenreither S,  Reddy SA, Lowe MC,  Beasley GM,  Gesierich A, Gschnell M,  Dummer R,  Arance A, Fenwick SW,  Sacco JJ,  John J, Wheater M,  Ottensmeier CH.
Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma.
J Cancer Res Clin Oncol 2025; 152(1): 25.
DOI: 10.1007/s00432-025-06291-x

Zager JS, Orloff M,  Ferrucci PF,  Choi J, Eschelman DJ,  Glazer ES,  Ejaz A, Howard JH,  Richtig E,  Ochsenreither S,  Reddy SA, Lowe MC,  Beasley GM,  Gesierich A, Bender A,  Gschnell M,  Dummer R, Rivoire M,  Arance A,  Fenwick SW, Sacco JJ,  Haferkamp S,  Weishaupt C, John J,  Wheater M,  Ottensmeier CH.
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.
Ann Surg Oncol 2025; 32(7): 4976-4988
DOI: 10.1245/s10434-025-17231-x

Lodde GC, Hassel JC,  von Wasielewski I,  Meier F,  Mohr P, Kähler K,  Hauschild A,  Glutsch V, Stege H,  Berking C,  Hüning S, Huynh J,  Gutzmer R,  Reinhardt L, Schilling B,  Loquai C,  Erdmann M, Stang A,  Kowall B,  Galetzka W, Roesch A,  Tilkorn D,  Ugurel S, Zimmer L,  Schadendorf D,  Forschner A, Livingstone E.
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma.
J Clin Oncol 2025; 43(25): 2793-2805
DOI: 10.1200/JCO-24-02776

Dummer R, Sandhu S,  Miller WH,  Butler MO, Taylor MH,  Heinzerling L,  Blank CU, Munoz-Couselo E,  Burris HA,  Postow MA, Chmielowski B,  Middleton MR,  Berking C, Hassel JC,  Gesierich AH,  Mauch C, Kleha JF,  Polli A,  Harney AS, di Pietro A,  Ascierto PA.
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.
Clin Cancer Res 2025; 31(11): 2097-2107
DOI: 10.1158/1078-0432.CCR-24-0254

Bachiri K, Kantar D,  Laurent EMN,  Gaboriaud P, Durand L,  Drouin A,  Chollot M, Schrama D,  Houben R,  Kervarrec T, Trapp-Fragnet L,  Touzé A,  Coyaud E.
DNA Damage Stress Control Is a Truncated Large T Antigen and Euchromatic Histone Lysine Methyltransferase 2-Dependent Central Feature of Merkel Cell Carcinoma.
J Invest Dermatol 2025; 145(2): 400-410.e4
DOI: 10.1016/j.jid.2024.04.034

Lodde GC,  Leiter U,  Gesierich A, Eigentler T,  Hauschild A,  Pföhler C, Gambichler T,  Herbst R,  Meier F, Hassel JC,  Meiß F,  Mohr P, Terheyden P,  Nikolakis G,  Hecht M, Stang A,  Dalkoohi M,  Galetzka W, Ugurel S,  Becker JC.
Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients.
Eur J Cancer 2025; 221: 115406.
DOI: 10.1016/j.ejca.2025.115406

Glatzel C,  Hansen-Abeck I,  Booken N, Düll J,  Goebeler M,  Schummer P, Wobser M.
Brentuximab vedotin as monotherapy or combination therapy for cutaneous peripheral T cell lymphoma - a retrospective study.
J Dtsch Dermatol Ges 2025; 23(11): 1424-1428
DOI: 10.1111/ddg.15826

Goller S, Goebeler M,  Wobser M.
Mogamulizumab-associated rash and lymphocytopenia coinciding with treatment response of Sézary syndrome.
Eur J Dermatol 2025; 35(4): 342-343
DOI: 10.1684/ejd.2025.4942

Wobser M,  Goebeler M,  Rosenwald A, Maurus K.
Topical ruxolitinib for treatment of mycosis fungoides and lymphomatoid papulosis.
Br J Dermatol 2025; 193(3): 563-564
DOI: 10.1093/bjd/ljaf180

Assaf C,  Booken N,  Dippel E,  Dobos G, Eich HT,  Klemke CD,  Mitteldorf C, Nicolay JP,  Theurich S,  Wobser M, Stadler R.
Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany.
J Dtsch Dermatol Ges 2025; 23(3): 341-354
DOI: 10.1111/ddg.15639

Drouin A,  Durand L,  Esnault C, Gaboriaud P,  Leblond V,  Karim S, Fouché M,  Dhommée C,  Baltus CB, Boursin F,  Aubrey N,  Houben R, Schrama D,  Guyétant S,  Desgranges A, Viaud-Massuard MC, Gouilleux-Gruart V,  Samimi M,  Kervarrec T,  Touzé A.
Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing cancers.
J Immunother Cancer 2025; 13(3): e010897
DOI: 10.1136/jitc-2024-010897

Becker JC,  Gesierich AH,  Leiter U, Zimmer L,  Hassel JC,  von Wasielewski I,  Ziemer M, Fluck M,  Meier F,  Spillner AN, Schilling B,  Eigentler TK,  Livingstone E,  Ugurel S, Angela Y,  Windemuth-Kieselbach C,  Gutzmer R.
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial.
Br J Dermatol 2025; 193(5): 865-875
DOI: 10.1093/bjd/ljaf303

DeTemple VK, Kaatz M,  Stockfleth E,  Scheel C, Angela Y,  Gutzmer R,  Leiter U, Meier F,  Schadendorf D,  Livingstone E,  Gebhardt C, von Wasielewski I,  Weichenthal M,  Mohr P,  Hassel J, Pföhler C,  Simon JC,  Jochims F, Terheyden P,  Ulrich J,  Haferkamp S, Drexler K,  Schilling B,  Glutsch V, Heinzerling L,  Berking C,  Ugurel S, Tomsitz D.
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.
Eur J Cancer 2025; 225: 115590
DOI: 10.1016/j.ejca.2025.115590

Ivanyi P, Alt-Epping B,  Bullinger L,  Gesierich A, Krabbe LM,  Münch U,  Pfitzner-Dempfle S,  Rieger C, Rittmeyer A,  Wiesing U,  Wolf M, Hofheinz RD,  Ivanyi P,  Vogel I.
Quality of Life of Cancer Patients in Routine Clinical Care Using the Example of Checkpoint Inhibition Therapy: A Delphi Consensus.
Oncology Research and Treatment 2025; 48(9): 498-505
DOI: 10.1159/000545513

Kalogirou C,  Krebs M,  Kunz AS, Hahn O,  Kübler H,  Schwinger M, Hartmann A,  Schmieder A,  Eckstein M.
Spatial transcriptomic profiling of metastatic renal cell carcinoma identifies chemokine-driven macrophage and CD8+ T-cell interactions predictive of immunotherapy response.
J Immunother Cancer 2025; 13(10): e012991.
DOI: 10.1136/jitc-2025-012991

Chanda T,  Hauser K, Hobelsberger S,  Bucher TC,  Garcia CN, Wies C,  Kittler H,  Tschandl P, Navarrete-Dechent C,  Podlipnik S,  Chousakos E,  Crnaric I, Majstorovic J,  Alhajwan L,  Foreman T, Peternel S,  Sarap S,  Özdemir İ, Barnhill RL,  Llamas-Velasco M,  Poch G,  Korsing S, Sondermann W,  Gellrich FF,  Heppt MV, Erdmann M,  Haferkamp S,  Drexler K, Goebeler M,  Schilling B,  Utikal JS, Ghoreschi K,  Fröhling S,  Krieghoff-Henning E,  Reader Study Consortium ,  Brinker TJ.
Dermatologist-like explainable AI enhances trust and confidence in diagnosing melanoma.
Nat Commun 2024; 15(1): 524.
DOI: 10.1038/s41467-023-43095-4

Koch EAT,  Petzold A,  Dippel E, Erdmann M,  Gesierich A,  Gutzmer R, Hassel JC,  Haferkamp S,  Kähler KC, Kreuzberg N,  Leiter U,  Loquai C, Meier F,  Meissner M,  Mohr P, Pföhler C,  Rahimi F,  Schell B, Terheyden P,  Thoms KM,  Ugurel S, Ulrich J,  Utikal J,  Weichenthal M,  Ziller F, Berking C,  Heppt MV.
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events.
Front Immunol 2024; 15:1395225.
DOI: 10.3389/fimmu.2024.1395225

Wohlfeil SA,  Kranzmann L,  Weiß C, von Wasielewski I,  Klespe KC,  Kähler KC,  Weichenthal M,  Schadendorf D,  Zimmer L, Mohr P,  Meier F,  Pfoehler C, Berking C,  Heppt MV,  Herbst R, Kreuter A,  Gutzmer R,  Ulrich J, Meiss F,  Gebhardt C,  Dippel E, Leiter U,  Schilling B,  Ugurel S, Utikal J.
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg.
Int J Cancer 2024; 155(10): 1808-1823
DOI: 10.1002/ijc.35078

Haggenmüller S, Schmitt M,  Krieghoff-Henning E,  Hekler A,  Maron RC, Wies C,  Utikal JS,  Meier F, Hobelsberger S,  Gellrich FF,  Sergon M, Hauschild A,  French LE,  Heinzerling L,  Schlager JG, Ghoreschi K,  Schlaak M,  Hilke FJ, Poch G,  Korsing S,  Berking C, Heppt MV,  Erdmann M,  Haferkamp S, Drexler K,  Schadendorf D,  Sondermann W, Goebeler M,  Schilling B,  Kather JN, Fröhling S,  Brinker TJ.
Federated Learning for Decentralized Artificial Intelligence in Melanoma Diagnostics.
JAMA Dermatol 2024; 160(3): 303-311
DOI: 10.1001/jamadermatol.2023.5550

Hekler A,  Maron RC,  Haggenmüller S,  Schmitt M, Wies C,  Utikal JS,  Meier F, Hobelsberger S,  Gellrich FF,  Sergon M, Hauschild A,  French LE,  Heinzerling L,  Schlager JG, Ghoreschi K,  Schlaak M,  Hilke FJ, Poch G,  Korsing S,  Berking C, Heppt MV,  Erdmann M,  Haferkamp S, Drexler K,  Schadendorf D,  Sondermann W, Goebeler M,  Schilling B,  Kather JN, Krieghoff-Henning E,  Brinker TJ.
Using multiple real-world dermoscopic photographs of one lesion improves melanoma classification via deep learning.
J Am Acad Dermatol 2024; 90(5): 1028-1031
DOI: 10.1016/j.jaad.2023.11.065

Wohlfarth J,  Kosnopfel C,  Faber D, Berthold M,  Siedel C,  Bernhardt M, Schlosser A,  Aprati T,  Liu D, Schrama D,  Houben R,  Schadendorf D,  Goebeler M, Meierjohann S,  Schilling B.
Loss of p14 diminishes immunogenicity in melanoma via non-canonical Wnt signaling by reducing the peptide surface density.
Mol Oncol 2024; 18(10): 2449-2470
DOI: 10.1002/1878-0261.13660

Zager JS,  Orloff M,  Ferrucci PF, Choi J,  Eschelman DJ,  Glazer ES, Ejaz A,  Howard JH,  Richtig E, Ochsenreither S,  Reddy SA,  Lowe MC, Beasley GM,  Gesierich A,  Bender A, Gschnell M,  Dummer R,  Rivoire M, Arance A,  Fenwick SW,  Sacco JJ, Haferkamp S,  Weishaupt C,  John J, Wheater M,  Ottensmeier CH.
Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Ann Surg Oncol 2024; 31(12): 8262-8263
DOI: 10.1245/s10434-024-15886-6

Zager JS, Orloff M,  Ferrucci PF,  Choi J, Eschelman DJ,  Glazer ES,  Ejaz A, Howard JH,  Richtig E,  Ochsenreither S,  Reddy SA, Lowe MC,  Beasley GM,  Gesierich A, Bender A,  Gschnell M,  Dummer R, Rivoire M,  Arance A,  Fenwick SW, Sacco JJ,  Haferkamp S,  Weishaupt C, John J,  Wheater M,  Ottensmeier CH.
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Ann Surg Oncol 2024; 31(8): 5340-5351
DOI: 10.1245/s10434-024-15293-x

Wendlinger S,  Wohlfarth J,  Siedel C, Kreft S,  Kilian T,  Junker S, Schmid L,  Sinnberg T,  Dischinger U, Heppt MV,  Wistuba-Hamprecht K,  Meier F,  Erpenbeck L, Neubert E,  Goebeler M,  Gesierich A, Schrama D,  Kosnopfel C,  Schilling B.
Susceptibility of Melanoma Cells to Targeted Therapy Correlates with Protection by Blood Neutrophils.
Cancers (Basel) 2024; 16(9): 1767.
DOI: 10.3390/cancers16091767

DeTemple VK,  Ritter C,  Srinivas N, Spassova I,  Gambichler T,  Hüning S, Gräger N,  Gutzmer R,  Bröcker EB, Ugurel S,  Schrama D,  Becker JC.
Short- and long-term immunosuppressive effects of melanoma influence the prognostic value of the sentinel lymph node status.
Eur J Cancer 2024; 212: 115054.
DOI: 10.1016/j.ejca.2024.115054

Fuchs L,  Gesierich A,  Schummer P, Schilling B.
Neoadjuvant therapy of melanoma.
Onkologie (Heidelberg, Germany) 2024; 30(5): 433-442
DOI: 10.1007/s00761-024-01506-1

Glutsch V,  Schummer P,  Goebeler M, Gesierich A,  Schilling B.
Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma.
Front Immunol 2024; 15: 1495004.
DOI: 10.3389/fimmu.2024.1495004

Kervarrec T,  Appenzeller S,  Gramlich S, Coyaud E,  Bachiri K,  Appay R, Macagno N,  Tallet A,  Bonenfant C, Lecorre Y,  Kapfer J,  Kettani S, Srinivas N,  Lei KC,  Lange A, Becker JC,  Sarosi EM,  Sartelet H, von Deimling A,  Touzé A,  Guyétant S, Samimi M,  Schrama D,  Houben R.
Analyses of combined Merkel cell carcinomas with neuroblastic components suggests that loss of T antigen expression in Merkel cell carcinoma may result in cell cycle arrest and neuroblastic transdifferentiation.
J Pathol 2024; 264(1): 112-124
DOI: 10.1002/path.6304

Becker JC, Stang A,  Schrama D,  Gutzmer R, Ugurel S.
An update on Merkel cell carcinoma.
Onkologie (Heidelberg, Germany) 2024; 30(9): 863-872
DOI: 10.1007/s00761-024-01577-0

Kervarrec T,  Appenzeller S,  Tallet A, Jullie ML,  Sohier P,  Guillonneau F,  Rütten A, Berthon P,  Le Corre Y,  Hainaut-Wierzbicka E,  Blom A, Beneton N,  Bens G,  Nardin C, Aubin F,  Dinulescu M,  Visée S, Herfs M,  Touzé A,  Guyétant S, Samimi M,  Houben R,  Schrama D.
Detection of wildtype Merkel cell polyomavirus genomic sequence and VP1 transcription in a subset of Merkel cell carcinoma.
Histopathology 2024; 84(2): 356-368
DOI: 10.1111/his.15068

Becker JC, Stang A,  Schrama D,  Ugurel S.
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates.
Am J Clin Dermatol 2024; 25(4): 541-557
DOI: 10.1007/s40257-024-00858-z

Gambichler T, Schrama D,  Käpynen R,  Weyer-Fahlbusch SS,  Becker JC, Susok L,  Kreppel F,  Abu Rached N.
Current Progress in Vaccines against Merkel Cell Carcinoma: A Narrative Review and Update.
Vaccines (Basel) 2024; 12(5): 533.
DOI: 10.3390/vaccines12050533

Durand MA,  Drouin A,  Bachiri K, Durand L,  Berthon P,  Houben R, Schrama D,  Coyaud E,  Samimi M, Touzé A,  Kervarrec T.
Enhancer of Zeste Homolog 2 Inhibition Induces HLA Class I Re-Expression in Merkel Cell Carcinoma.
J Invest Dermatol 2024; 144(6): 1398-1401.e1
DOI: 10.1016/j.jid.2023.10.036

Zvulunov A,  Neale H,  Stern J, Santaguida P,  Stein AB,  Koh M, Eichenfield LF,  Guitart J,  Goebeler M, Scarisbrick J,  Willemze R,  Coughlin CC, George R,  Brazzelli V,  Marschalkó M, Belousova I,  Querfeld C,  Bagot M, Szepietowski JC,  Papadavid E,  Quaglino P,  Hoeger P, Ortiz-Romero PL,  Nikolaou V,  Dummer R, Aung PP,  Lawley L,  Morel KD, Ngan B,  Wain M,  Gameiro A, Lacy-Niebla RM,  Pope E.
Approach to Mycosis Fungoides in children: Consensus-based recommendations.
J Am Acad Dermatol 2024; 91(6): 1078-1085
DOI: 10.1016/j.jaad.2024.07.1501

Winkler M,  Albrecht JD,  Sauer C, Kordaß T,  Guenova E,  Livingstone E,  Wobser M, Mitteldorf C,  Géraud C,  Nicolay JP.
Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type: A case series and review of the literature.
J Dermatol 2024; 51(9): 1233-1239
DOI: 10.1111/1346-8138.17339

Hansen-Abeck I,  Geidel G,  Abeck F, Kött J,  Cankaya R,  Dobos G, Mitteldorf C,  Nicolay JP,  Albrecht JD, Menzer C,  Livingstone E,  Mengoni M, Braun AD,  Wobser M,  Klemke CD, Tratzmiller S,  Assaf C,  Terheyden P, Klespe KC,  Schneider SW,  Booken N.
Pegylated interferon-α2a in cutaneous T-cell lymphoma - a multicenter retrospective data analysis with 70 patients.
J Dtsch Dermatol Ges 2024; 22(11): 1489-1497
DOI: 10.1111/ddg.15511

Vadivel CK,  Willerslev-Olsen A,  Namini MRJ, Zeng Z,  Yan L,  Danielsen M, Gluud M,  Pallesen EMH,  Wojewoda K, Osmancevic A,  Hedebo S,  Chang YT, Lindahl LM,  Koralov SB,  Geskin LJ, Bates SE,  Iversen L,  Litman T, Bech R,  Wobser M,  Guenova E, Kamstrup MR,  Ødum N,  Buus TB.
Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome.
Blood 2024; 143(15): 1496-1512
DOI: 10.1182/blood.2023021671

Dege T,  Netzer I,  Strobel K, Goebeler M,  Wobser M.
Successful treatment of lymphomatoid papulosis with chlormethine gel.
J Dtsch Dermatol Ges 2024; 22(6): 826-827
DOI: 10.1111/ddg.15371

Glutsch V,  Schummer P,  Koschker AC, Goebeler M,  Wobser M.
Adrenal Insufficiency after Long-term use of Topical Glucocorticoids in Patients with Advanced Cutaneous T-cell Lymphomas: A Case Series.
Acta Derm Venereol 2024; 104: adv19672.
DOI: 10.2340/actadv.v104.19672

Wobser M, Appenzeller S,  Roth S,  Siedel C, Goebeler M,  Geissinger E,  Rosenwald A, Maurus K.
Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder.
Br J Dermatol 2024; 191(5): 816-822
DOI: 10.1093/bjd/ljae256

Kervarrec T, Cheok Lei K,  Sohier P,  Macagno N, Jullie ML,  Frouin E,  Goto K, Taniguchi K,  Hamard A,  Taillandier A,  Tallet A, Bonenfant C,  Sahin Y,  Barry F, Taibjee S,  Cokelaere K,  Houben R, Schrama D,  Nardin C,  Aubin F, Doucet L,  Pissaloux D,  Tirode F, Fouchardière A,  Balme B,  Laurent-Roussel S,  Becker JC, von Deimling A,  Samimi M,  Cribier B, Battistella M,  Calonje E,  Guyétan S.
Wnt/β-Catenin-Activated Nonpilomatrical Carcinoma of the Skin: A Case Series.
Mod Pathol 2024; 37(11): 100586.
DOI: 10.1016/j.modpat.2024.100586

Gonzalez JM, Rosell-Diaz AM,  Chircop I,  Le AM, Dege T,  Byrne N,  Reynaud V, Garcia-Piqueras P.
Journal Club: Histiocytoses.
Eur J Dermatol 2024; 34(4): 450-453
DOI: 10.1684/ejd.2024.4745

Haggenmüller S, Maron RC,  Hekler A,  Krieghoff-Henning E,  Utikal JS, Gaiser M,  Müller V,  Fabian S, Meier F,  Hobelsberger S,  Gellrich FF, Sergon M,  Hauschild A,  Weichenthal M,  French LE, Heinzerling L,  Schlager JG,  Ghoreschi K, Schlaak M,  Hilke FJ,  Poch G, Korsing S,  Berking C,  Heppt MV, Erdmann M,  Haferkamp S,  Drexler K, Schadendorf D,  Sondermann W,  Goebeler M, Schilling B,  Kather JN,  Fröhling S, Kaminski K,  Doppler A,  Bucher T, Brinker TJ,  Collaborators .
Patients' and dermatologists' preferences in artificial intelligence-driven skin cancer diagnostics: A prospective multicentric survey study.
J Am Acad Dermatol 2024; 91(2): 366-370
DOI: 10.1016/j.jaad.2024.04.033

Ruf T,  Kramer R,  Forschner A, Leiter U,  Meier F,  Reinhardt L, Duecker P,  Ertl C,  Tomsitz D, Tietze JK,  Gutzmer R,  Dabrowski E, Zimmer L,  Gesierich A,  Zierold S, French LE,  Eigentler T,  Amaral T, Heinzerling L.
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
Eur J Cancer 2024; 203: 114028.
DOI: 10.1016/j.ejca.2024.114028

Van Passen C,  Krug J,  Weiss L, Krueger R,  Abdou MM,  Busenhart P, Scharl M,  Naschberger E,  Stuerzl M.
Integrin β6 mediates binding of disseminated colorectal cancer cells to   endothelial cell.
Oncology Research and Treatment 2024; 47 Suppl 1:58-58

Hoeger PH,  Hamm H.
Contact cryotherapy of infantile hemangiomas-No longer a real option.
Monatsschr Kinderheilkd 2024; 172(1): 72-74
DOI: 10.1007/s00112-023-01881-w

Thiem A,  Mashhadiakbar P,  Cussigh C, Hassel JC,  Grimmelmann I,  Gutzmer R, Schlaak M,  Heppt MV,  Dücker P, Hüning S,  Schulmeyer L,  Schilling B, Haferkamp S,  Ziemer M,  Moritz RKC, Hagelstein V,  Terheyden P,  Posch C, Gaiser MR,  Kropp P,  Emmert S, Müller B,  Tietze JK.
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study.
J Eur Acad Dermatol Venereol 2023; 37(5): 884-893
DOI: 10.1111/jdv.18778

Hench J, Mihic-Probst D,  Agaimy A,  Frank S, Meyer P,  Hultschig C,  Simi S, Alos L,  Balamurugan T,  Blokx W, Bosisio F,  Cappellesso R,  Griewank K, Hadaschik E,  van Kempen LC,  Kempf W, Lentini M,  Mazzucchelli L,  Rinaldi G, Rutkowski P,  Schadendorf D,  Schilling B, Szumera-Cieckiewicz A,  van den Oord J,  Mandalà M,  Massi D, EORTC Melanoma Group .
Clinical, histopathological and molecular features of dedifferentiated melanomas: An EORTC Melanoma Group Retrospective Analysis.
Eur J Cancer 2023; 187: 7-14
DOI: 10.1016/j.ejca.2023.03.032

Niessner H,  Hüsch A,  Kosnopfel C, Meinhardt M,  Westphal D,  Meier F, Schilling B,  Sinnberg T.
Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma.
Cancers (Basel) 2023; 15(23): 5521.
DOI: 10.3390/cancers15235521

Lodde GC,  Hassel J,  Wulfken LM, Meier F,  Mohr P,  Kähler K, Hauschild A,  Schilling B,  Loquai C, Berking C,  Hüning S,  Eckardt J, Gutzmer R,  Reinhardt L,  Glutsch V, Nikfarjam U,  Erdmann M,  Beckmann CL, Stang A,  Kowall B,  Galetzka W, Roesch A,  Ugurel S,  Zimmer L, Schadendorf D,  Forschner A,  Livingstone E.
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study.
Eur J Cancer 2023; 191: 112957.
DOI: 10.1016/j.ejca.2023.112957

Koch EAT,  Petzold A,  Wessely A, Dippel E,  Eckstein M,  Gesierich A, Gutzmer R,  Hassel JC,  Knorr H, Kreuzberg N,  Leiter U,  Loquai C, Meier F,  Meissner M,  Mohr P, Pföhler C,  Rahimi F,  Schadendorf D,  Schlaak M, Thoms KM,  Ugurel S,  Utikal J, Weichenthal M,  Schuler-Thurner B,  Berking C,  Heppt MV.
Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial.
Front Med 2023; 17(5): 878-888
DOI: 10.1007/s11684-023-0993-y

Scherzad A,  Stöth M,  Meyer TJ, Haug L,  Gehrke T,  Schilling B, Meierjohann S,  Scheich M,  Hagen R, Gesierich A,  Hackenberg S.
Multimodal treatment and immune checkpoint inhibition in sinonasal mucosal melanoma: real-world data of a retrospective, single-center study.
Eur Arch Otorhinolaryngol 2023; 280(9): 4215-4223
DOI: 10.1007/s00405-023-08015-8

Thompson JF, Hyngstrom J,  Caracò C,  Zager JS, Jahkola T,  Bowles TL,  Pennacchioli E,  Hoekstra HJ, Moncrieff M,  Ingvar C,  van Akkooi A, Sabel MS,  Levine EA,  Henderson M, Dummer R,  Rossi CR,  Kane JM, Trocha S,  Wright F,  Byrd DR, Matter M,  MacKenzie-Ross A,  Kelley MC, Terheyden P,  Huston TL,  Wayne JD, Neuman H,  Smithers BM,  Desai D, Gershenwald JE,  Schneebaum S,  Gesierich A,  Jacobs LK, Lewis JM,  O'Donoghue C,  Sardi A, McKinnon JG,  Slingluff CL,  Farma JM, Schultz E,  Scheri RP,  Vidal-Sicart S,  Testori AAE, Scolyer RA,  Elashoff DE,  Cochran AJ, Faries MB.
Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma.
Ann Surg Oncol 2023; 30(7): 4359-4360
DOI: 10.1245/s10434-023-13570-9

Gesierich A, Schilling B.
Adjuvant therapy for melanoma
Onkologie (Heidelberg, Germany) 2023; 29(671–679):
DOI: 10.1007/s00761-023-01376-z

Barbieux S, Tallet A,  Collin C,  Tallegas M, Delalande F,  Bens G,  Levy A, Kalampokas A,  Schrama D,  Houben R, Touzé A,  Garcia J,  Macagno N, Appay R,  Samimi M,  Guyétant S, Kervarrec T.
Genetic evidence of a sarcomatoid transformation in Merkel cell carcinoma.
J Eur Acad Dermatol Venereol 2023; 37(1): e45-e48
DOI: 10.1111/jdv.18529

Wobser M, Goebeler M.
Special Issue "Cutaneous Lymphomas".
Cancers (Basel) 2023; 15(5): 1481.
DOI: 10.3390/cancers15051481

Nicolay JP,  Melchers S,  Albrecht JD, Assaf C,  Dippel E,  Stadler R, Wehkamp U,  Wobser M,  Zhao J, Burghaus I,  Schneider S,  Gülow K, Goerdt S,  Schürch CM,  Utikal JS, Krammer PH.
Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study.
Blood 2023; 142(9): 794-805
DOI: 10.1182/blood.2022018669

Haake M,  Haack B,  Schäfer T,  Harter PN, Mattavelli G,  Eiring P,  Vashist N, Wedekink F,  Genssler S,  Fischer B, Dahlhoff J,  Mokhtari F,  Kuzkina A, Welters MJP,  Benz TM,  Sorger L, Thiemann V,  Almanzar G,  Selle M, Thein K,  Späth J,  Gonzalez MC, Reitinger C,  Ipsen-Escobedo A,  Wistuba-Hamprecht K,  Eichler K, Filipski K,  Zeiner PS,  Beschorner R, Goedemans R,  Gogolla FH,  Hackl H, Rooswinkel RW,  Thiem A,  Roche PR, Joshi H,  Pühringer D,  Wöckel A, Diessner JE,  Rüdiger M,  Leo E, Cheng PF,  Levesque MP,  Goebeler M, Sauer M,  Nimmerjahn F,  Schuberth-Wagner C,  von Felten S, Mittelbronn M,  Mehling M,  Beilhack A, van der Burg SH,  Riedel A,  Weide B, Dummer R,  Wischhusen J.
Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment.
Nat Commun 2023; 14(1):4253.
DOI: 10.1038/s41467-023-39817-3

Mohme S,  Alband N,  Diaz AR, Lefevre MA,  Lomba ER,  Nogueira M, Goebeler M,  Hamm H.
Journal Club: Longitudinal melanonychia in children: keep calm, wait and see.
Eur J Dermatol 2023; 33(1): 60-72
DOI: 10.1684/ejd.2023.4444

Dege T,  Goebeler M,  Kneitz H.
Collision tumour of desmoplastic trichoepithelioma and melanocytic compound nevus.
Eur J Dermatol 2023; 33(4): 455-457
DOI: 10.1684/ejd.2023.4543

Dege T,  Maurus K,  Kneitz H, Presser D,  Kunstmann E,  Schilling B.
A nonsense mutation in SUFU associated with multiple infundibulocystic basal cell carcinomas.
J Dtsch Dermatol Ges 2023; 21(11): 1396-1398
DOI: 10.1111/ddg.15190

Livingstone E,  Zimmer L,  Hassel JC, Fluck M,  Eigentler TK,  Loquai C, Haferkamp S,  Gutzmer R,  Meier F, Mohr P,  Hauschild A,  Schilling B, Menzer C,  Kiecker F,  Dippel E, Roesch A,  Ziemer M,  Conrad B, Körner S,  Windemuth-Kieselbach C,  Schwarz L,  Garbe C, Becker JC,  Schadendorf D,  Dermatologic Cooperative Oncology Group. 
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Lancet 2022; 400(10358): 1117-1129
DOI: 10.1016/S0140-6736(22)01654-3

Leikeim A,  Wußmann M,  Schmidt FF, Neto NGB,  Benz F,  Tiltmann K, Junger C,  Monaghan MG,  Schilling B, Groeber-Becker FK.
A preclinical model of cutaneous melanoma based on reconstructed human epidermis.
Sci Rep 2022; 12(1): 16269.
DOI: 10.1038/s41598-022-19307-0

Schummer P,  Schilling B.
How representative are data from global trials on programmed death-1 blockade in melanoma?
Br J Dermatol 2022; 187(3): 283-284
DOI: 10.1111/bjd.21621

Isberner N, Gesierich A,  Balakirouchenane D,  Schilling B,  Aghai-Trommeschlaeger F,  Zimmermann S, Kurlbaum M,  Puszkiel A,  Blanchet B, Klinker H,  Scherf-Clavel O.
Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma.
Cancers (Basel) 2022; 14(19): 4566.
DOI: 10.3390/cancers14194566

Lodde GC, Jansen P,  Möller I,  Sucker A, Hassel JC,  Forschner A,  Eckardt J, Meier F,  Reinhardt L,  Kähler KC, Ziemer M,  Schlaak M,  Rahimi F, Schatton K,  Meiss F,  Gutzmer R, Pföhler C,  Terheyden P,  Schilling B, Sachse M,  Heppt MV,  Sindrilaru A, Leiter U,  Zaremba A,  Thielmann CM, Ugurel S,  Zimmer L,  Hadaschik E, Bechrakis NE,  Schadendorf D,  Westekemper H,  Livingstone E,  Griewank KG, German Dermatologic Cooperative Oncology Group (DeCOG, committee ocular melanoma) .
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.
Eur J Cancer 2022; 166:60-72
DOI: 10.1016/j.ejca.2022.01.008

Wendlinger S,  Wohlfarth J,  Kreft S, Siedel C,  Kilian T,  Dischinger U, Heppt MV,  Wistuba-Hamprecht K,  Meier F,  Goebeler M, Schadendorf D,  Gesierich A,  Kosnopfel C, Schilling B.
Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma.
Cancers (Basel) 2022; 14(9): 2294.
DOI: 10.3390/cancers14092294

Schmidt M,  Mortensen LS,  Loeffler-Wirth H,  Kosnopfel C, Krohn K,  Binder H,  Kunz M.
Single-cell trajectories of melanoma cell resistance to targeted treatment.
Cancer Biol Med 2022; 19(1): 56-73
DOI: 10.20892/j.issn.2095-3941.2021.0267

Kreft S, Glutsch V,  Zaremba A,  Schummer P, Mohr P,  Grimmelmann I,  Gutzmer R, Meier F,  Pföhler C,  Sachse MM, Meiss F,  Forschner A,  Haferkamp S, Welzel J,  Terheyden P,  Herbst R, Utikal J,  Kaatz M,  Weishaupt C, Kreuter A,  Debus D,  Duecker P, Sindrilaru A,  Löffler H,  Schley G, Weichenthal M,  Schadendorf D,  Ugurel S,  Gesierich A, Schilling B.
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
Eur J Cancer 2022; 167: 32-41
DOI: 10.1016/j.ejca.2022.02.023

Garbe C,  Keim U,  Amaral T,  Berking C, Eigentler TK,  Flatz L,  Gesierich A, Leiter U,  Stadler R,  Sunderkötter C,  Tüting T, Utikal J,  Wollina U,  Zimmer L, Zouboulis CC,  Ascierto PA,  Eggermont AMM,  Grob JJ, Hauschild A,  Sekulovic LK,  Long GV, Luke JJ,  Michielin O,  Peris K, Schadendorf D,  Kirkwood JM,  Lorigan PC.
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
J Clin Oncol 2022; 40(32): 3741-3749
DOI: 10.1200/JCO.22.00202

Multicenter Selective Lymphadenectomy Trials Study Group ,  Crystal JS,  Thompson JF, Hyngstrom J,  Caracò C,  Zager JS, Jahkola T,  Bowles TL,  Pennacchioli E,  Beitsch PD, Hoekstra HJ,  Moncrieff M,  Ingvar C, van Akkooi A,  Sabel MS,  Levine EA, Agnese D,  Henderson M,  Dummer R, Neves RI,  Rossi CR,  Kane JM, Trocha S,  Wright F,  Byrd DR, Matter M,  Hsueh EC,  MacKenzie-Ross A,  Kelley M, Terheyden P,  Huston TL,  Wayne JD, Neuman H,  Smithers BM,  Ariyan CE, Desai D,  Gershenwald JE,  Schneebaum S, Gesierich A,  Jacobs LK,  Lewis JM, McMasters KM,  O'Donoghue C,  van der Westhuizen A,  Sardi A, Barth R,  Barone R,  McKinnon JG, Slingluff CL,  Farma JM,  Schultz E, Scheri RP,  Vidal-Sicart S,  Molina M, Testori AAE,  Foshag LJ,  Van Kreuningen L,  Wang HJ, Sim MS,  Scolyer RA,  Elashoff DE, Cochran AJ,  Faries MB.
Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial.
JAMA Surg 2022; 157(9): 835-842
DOI: 10.1001/jamasurg.2022.2055

Koch EAT, Petzold A,  Wessely A,  Dippel E, Gesierich A,  Gutzmer R,  Hassel JC, Haferkamp S,  Kähler KC,  Knorr H, Kreuzberg N,  Leiter U,  Loquai C, Meier F,  Meissner M,  Mohr P, Pföhler C,  Rahimi F,  Schadendorf D,  Schell B, Schlaak M,  Terheyden P,  Thoms KM, Schuler-Thurner B,  Ugurel S,  Ulrich J, Utikal J,  Weichenthal M,  Ziller F, Berking C,  Heppt MV.
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity.
Cancers (Basel) 2022; 14(3): 518.
DOI: 10.3390/cancers14030518

Goldinger SM, Buder-Bakhaya K,  Lo SN,  Forschner A, McKean M,  Zimmer L,  Khoo C, Dummer R,  Eroglu Z,  Buchbinder EI,  Ascierto PA, Gutzmer R,  Rozeman EA,  Hoeller C, Johnson DB,  Gesierich A,  Kölblinger P, Bennannoune N,  Cohen JV,  Kähler KC, Wilson MA,  Cebon J,  Atkinson V, Smith JL,  Michielin O,  Long GV, Hassel JC,  Weide B,  Haydu LE, Schadendorf D,  McArthur G,  Ott PA, Blank C,  Robert C,  Sullivan R, Hauschild A,  Carlino MS,  Garbe C, Davies MA,  Menzies AM.
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
Eur J Cancer 2022; 162:22-33
DOI: 10.1016/j.ejca.2021.11.022

Banicka V,  Martens MC,  Panzer R, Schrama D,  Emmert S,  Boeckmann L, Thiem A.
Homozygous CRISPR/Cas9 Knockout Generated a Novel Functionally Active Exon 1 Skipping XPA Variant in Melanoma Cells.
Int J Mol Sci 2022; 23(19): 11649.
DOI: 10.3390/ijms231911649

Glutsch V,  Wobser M,  Schilling B, Gesierich A,  Goebeler M,  Kneitz H.
PRAME Expression as Helpful Immunohistochemical Marker in Rhabdoid Melanoma.
Dermatopathology (Basel) 2022; 9(2): 148-157
DOI: 10.3390/dermatopathology9020019

Tawbi HA, Schadendorf D,  Lipson EJ,  Ascierto PA, Matamala L,  Castillo Gutiérrez E,  Rutkowski P,  Gogas HJ, Lao CD,  De Menezes JJ,  Dalle S, Arance A,  Grob JJ,  Srivastava S, Abaskharoun M,  Hamilton M,  Keidel S, Simonsen KL,  Sobiesk AM,  Li B, Hodi FS,  Long GV,  RELATIVITY-047 Investigators .
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
N Engl J Med 2022; 386(1): 24-34
DOI: 10.1056/NEJMoa2109970

Glutsch V,  Schummer P,  Kneitz H, Gesierich A,  Goebeler M,  Klein D, Posch C,  Gebhardt C,  Haferkamp S, Zimmer L,  Becker JC,  Leiter U, Weichenthal M,  Schadendorf D,  Ugurel S,  Schilling B.
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG.
J Immunother Cancer 2022; 10(11): e005930.
DOI: 10.1136/jitc-2022-005930

Kervarrec T, Appenzeller S,  Samimi M,  Sarma B, Sarosi EM,  Berthon P,  Le Corre Y, Hainaut-Wierzbicka E,  Blom A,  Benethon N,  Bens G, Nardin C,  Aubin F,  Dinulescu M, Jullie ML,  Pekár-Lukacs Á,  Calonje E, Thanguturi S,  Tallet A,  Wobser M, Touzé A,  Guyétant S,  Houben R, Schrama D.
Merkel Cell Polyomavirus‒Negative Merkel Cell Carcinoma Originating from In Situ Squamous Cell Carcinoma: A Keratinocytic Tumor with Neuroendocrine Differentiation.
J Invest Dermatol 2022; 142(3 Pt A):516-527
DOI: 10.1016/j.jid.2021.07.175

Houben R,  Hesbacher S,  Sarma B, Schulte C,  Sarosi EM,  Popp S, Adam C,  Kervarrec T,  Schrama D.
Inhibition of T-antigen expression promoting glycogen synthase kinase 3 impairs merkel cell carcinoma cell growth.
Cancer Lett 2022; 524:259-267
DOI: 10.1016/j.canlet.2021.10.031

Kervarrec T,  Chéret J,  Paus R, Houben R,  Schrama D.
Transduction-induced overexpression of Merkel cell T antigens in human hair follicles induces formation of pathological cell clusters with Merkel cell carcinoma-like phenotype.
Exp Dermatol 2022; 31(2): 259-260
DOI: 10.1111/exd.14447

Esnault C, Leblond V,  Martin C,  Desgranges A, Baltus CB,  Aubrey N,  Lakhrif Z, Lajoie L,  Lantier L,  Clémenceau B, Sarma B,  Schrama J,  Houben R, Schrama D,  Hesbacher S,  Gouilleux-Gruart V,  Feng Y, Dimitrov D,  Guyétant S,  Berthon P, Viaud-Massuard MC,  Samimi M,  Touzé A, Kervarrec T.
Adcitmer® , a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma.
Br J Dermatol 2022; 186(2): 295-306
DOI: 10.1111/bjd.20770

Thanguturi S, Tallet A,  Miquelestorena-Standley E,  Coco C,  Le Corre Y, Hainaut-Wierzbicka E,  Blom A,  Saiag P,  Beneton N, Bens G,  Zaragoza J,  Nardin C, Aubin F,  Dinulescu M,  Machet MC, Houben R,  Schrama D,  Collin C, Fromont G,  Jullie ML,  Macagno N, Gaboriaud P,  Berthon P,  Touzé A, Guyétant S,  Samimi M,  Kervarrec T.
Investigation of the RB1-SOX2 axis constitutes a tool for viral status determination and diagnosis in Merkel cell carcinoma.
Virchows Arch 2022; 480(6): 1239-1254
DOI: 10.1007/s00428-022-03315-6

Wobser M, Schummer P,  Appenzeller S,  Kneitz H, Roth S,  Goebeler M,  Geissinger E, Rosenwald A,  Maurus K.
Panel Sequencing of Primary Cutaneous B-Cell Lymphoma.
Cancers (Basel) 2022; 14(21): 5274.
DOI: 10.3390/cancers14215274

Dippel E,  Assaf C,  Becker JC,  von Bergwelt-Baildon M,  Bernreiter S, Cozzio A,  Eich HT,  Elsayad K, Follmann M,  Grabbe S,  Hillen U, Klapper W,  Klemke CD,  Loquai C, Meiss F,  Mitteldorf C,  Wehkamp U, Nashan D,  Nicolay JP,  Oschlies I, Schlaak M,  Stranzenbach R,  Moritz R, Stoll C,  Vag T,  Weichenthal M,  Wobser M, Stadler R.
S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021.
J Dtsch Dermatol Ges 2022; 20(4): 537-554
DOI: 10.1111/ddg.14706

Kempf W,  Petrella T,  Willemze R, Jansen P,  Berti E,  Santucci M, Geissinger E,  Cerroni L,  Maubec E, Battistella M,  Goodlad J,  Guenova E, Lappalainen K,  Ranki A,  Craig P, Calonje E,  Martin B,  Whittaker S, Oschlies I,  Wehkamp U,  Nicolay JP, Wobser M,  Scarisbruck J,  Pimpinelli N, Stadler R,  Kerl French K,  Quaglino P, Lin J,  Chen L,  Beer M, Emanuel P,  Dalle S,  Robson A.
Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop.
Br J Dermatol 2022; 186(5): 887-897
DOI: 10.1111/bjd.20973

Hofer V,  Maurus K,  Houben R,  Schrama D, Roth S,  Goebeler M,  Geissinger E, Rosenwald A,  Wobser M.
Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.
J Cutan Pathol 2022; 49(3): 314-317
DOI: 10.1111/cup.14178

Assaf C,  Booken N,  Dippel E,  Guenova E, Jonak C,  Klemke CD,  Nicolay JP, Schlaak M,  Wobser M,  Trautinger F.
The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region).
J Dtsch Dermatol Ges 2022; 20(5): 579-586
DOI: 10.1111/ddg.14688

Blazejak C,  Stranzenbach R,  Gosman J, Gambichler T,  Wehkamp U,  Stendel S, Klemke CD,  Wobser M,  Olk J, Nicolay JP,  Weyermann M,  Stadler R, Assaf C.
Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network.
Dermatology 2022; 238(3): 498-506
DOI: 10.1159/000517830

Sorger H,  Dey S,  Vieyra-Garcia PA,  Poeloeske D, Teufelberger AR,  de Araujo ED,  Sedighi A,  Graf R, Spiegl B,  Lazzeri I,  Braun T, Alonso IGD,  Schlederer M,  Timelthaler G,  Kodajova P, Pirker C,  Surbek M,  Machtinger M, Graier T,  Perchthaler I,  Pan Y, Fink-Puches R,  Cerroni L,  Ober J, Otte M,  Albrecht JD,  Tin G, Abdeldayem A,  Manaswiyoungkul P,  Olaoye OO,  Metzelder ML, Orlova A,  Berger W,  Wobser M, Nicolay JP,  Andre F,  Nguyen V, Neubauer HA,  Fleck R,  Merkel O, Herling M,  Heitzer E,  Gunning PT, Kenner L,  Moriggl R,  Wolf P.
Blocking STAT3/5 through direct or upstream kinase targeting in leukemic   cutaneous T-cell lymphoma
EMBO Mol Med 2022; 14(12): e15200.
DOI: 10.15252/emmm.202115200

Hauser K,  Kurz A,  Haggenmüller S,  Maron RC, von Kalle C,  Utikal JS,  Meier F, Hobelsberger S,  Gellrich FF,  Sergon M, Hauschild A,  French LE,  Heinzerling L,  Schlager JG, Ghoreschi K,  Schlaak M,  Hilke FJ, Poch G,  Kutzner H,  Berking C, Heppt MV,  Erdmann M,  Haferkamp S, Schadendorf D,  Sondermann W,  Goebeler M, Schilling B,  Kather JN,  Fröhling S, Lipka DB,  Hekler A,  Krieghoff-Henning E,  Brinker TJ.
Explainable artificial intelligence in skin cancer recognition: A systematic review.
Eur J Cancer 2022; 167:54-69
DOI: 10.1016/j.ejca.2022.02.025

Graen F, Schilling B.
Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors.
Aktuelle Rheumatol 2022; 47(04): 344-352
DOI: 10.1055/a-1794-9687

Haist M,  Stege H,  Lang BM,  Tsochataridou A,  Salzmann M, Mohr P,  Schadendorf D,  Ugurel S, Placke JM,  Weichenthal M,  Gutzmer R, Leiter U,  Kaatz M,  Haferkamp S, Berking C,  Heppt M,  Tschechne B, Schummer P,  Gebhardt C,  Grabbe S, Loquai C.
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry.
Cancers (Basel) 2022; 14(22): 5543.
DOI: 10.3390/cancers14225543

Kervarrec T, Pissaloux D,  Poilane J,  Tirode F, Tallet A,  Collin C,  Tallegas M, Berthon P,  Gaboriaud P,  Sohier P, Calonje E,  Luzar B,  Goto K, Cokelaere K,  Lamant L,  Balme B, Wild R,  Neuville A,  Deschamps L, Auberger E,  Paumier V,  Bonte H, Moulonguet I,  Plantier F,  Cales V, Pinsolle V,  Roblet D,  Dupuy F, Dallot A,  Seris A,  Jouary T, Houben R,  Schrama D,  Hesbacher S, Macagno N,  Battistella M,  Cribier B, Vergier B,  de la Fouchardière A,  Jullie ML.
Recurrent FOXK1::GRHL and GPS2::GRHL fusions in trichogerminoma.
J Pathol 2022; 257(1): 96-108
DOI: 10.1002/path.5872

Benedikt Westphalen C, Bokemeyer C,  Büttner R,  Fröhling S, Gaidzik VI,  Glimm H,  Hacker UT, Heinemann V,  Illert AL,  Keilholz U, Kindler T,  Kirschner M,  Schilling B, Siveke JT,  Schroeder T,  Tischler V, Wagner S,  Weichert W,  Zips D, Loges S,  Working Group Molecular Diagnostics and Therapy.
Corrigendum to "Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'" [European Journal of Cancer 135 (2020) 1-7].
Eur J Cancer 2022; 162:245-246
DOI: 10.1016/j.ejca.2021.11.014

Strobel K, Maurus K,  Hamm H,  Roth S, Goebeler M,  Rosenwald A,  Wobser M.
Recurrent Alterations in the MAPK pathway in Sporadic Pyogenic Granuloma of Childhood.
Acta Derm Venereol 2022; 102: adv00715.
DOI: 10.2340/actadv.v102.1119

Friedmann Angeli JP,  Xavier da Silva TN,  Schilling B.
CD8+ T cells PUF(A)ing the flames of cancer ferroptotic cell death.
Cancer Cell 2022; 40(4): 346-348
DOI: 10.1016/j.ccell.2022.03.003

Esnault C, Schrama D,  Houben R,  Guyétant S, Desgranges A,  Martin C,  Berthon P, Viaud-Massuard MC,  Touzé A,  Kervarrec T, Samimi M.
Antibody-Drug Conjugates as an Emerging Therapy in Oncodermatology.
Cancers (Basel) 2022; 14(3): 778.
DOI: 10.3390/cancers14030778

Maurus K, Kosnopfel C,  Kneitz H,  Appenzeller S,  Schrama D, Glutsch V,  Roth S,  Gerhard-Hartmann E,  Rosenfeldt M, Möhrmann L,  Fröhlich M,  Hübschmann D, Stenzinger A,  Glimm H,  Fröhling S, Goebeler M,  Rosenwald A,  Kutzner H, Schilling B.
Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen-activated protein kinase pathway.
Br J Dermatol 2022; 186(3): 553-563
DOI: 10.1111/bjd.20869

Maron RC, Hekler A,  Haggenmüller S,  von Kalle C, Utikal JS,  Müller V,  Gaiser M, Meier F,  Hobelsberger S,  Gellrich FF, Sergon M,  Hauschild A,  French LE, Heinzerling L,  Schlager JG,  Ghoreschi K, Schlaak M,  Hilke FJ,  Poch G, Korsing S,  Berking C,  Heppt MV, Erdmann M,  Haferkamp S,  Schadendorf D,  Sondermann W, Goebeler M,  Schilling B,  Kather JN, Fröhling S,  Lipka DB,  Krieghoff-Henning E,  Brinker TJ.
Model soups improve performance of dermoscopic skin cancer classifiers.
Eur J Cancer 2022; 173:307-316
DOI: 10.1016/j.ejca.2022.07.002

Müller-Jensen L, Zierold S,  Versluis JM,  Boehmerle W, Huehnchen P,  Endres M,  Mohr R, Compter A,  Blank CU,  Hagenacker T, Meier F,  Reinhardt L,  Gesierich A, Salzmann M,  Hassel JC,  Ugurel S, Zimmer L,  Banks P,  Spain L, Soon JA,  Enokida T,  Tahara M, Kähler KC,  Seggewiss-Bernhardt R,  Harvey C,  Long GV, Schöberl F,  von Baumgarten L,  Hundsberger T,  Schlaak M, French LE,  Knauss S,  Heinzerling LM.
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.
Eur J Cancer 2022; 175:224-235
DOI: 10.1016/j.ejca.2022.08.009

Jebli Y,  Mohme S,  Alband N,  Nogueira M, Rosell Diaz A,  Rodriguez-Lomba E,  Lefevre MA.
Journal Club: Non-invasive imaging tools in daily onco-dermatology practice.
Eur J Dermatol 2022; 32(6): 810-812
DOI: 10.1684/ejd.2022.4383

Kneitz H,  Rose C,  Glutsch V, Goebeler M.
Recurrence of a Cellular Blue Nevus with Satellitosis-A Diagnostic Pitfall with Clinical Consequences.
Dermatopathology (Basel) 2022; 9(4): 361-367
DOI: 10.3390/dermatopathology9040042

Müller-Jensen L, Zierold S,  Versluis JM,  Boehmerle W, Huehnchen P,  Endres M,  Mohr R, Compter A,  Blank CU,  Hagenacker T, Meier F,  Reinhardt L,  Gesierich A, Salzmann M,  Hassel JC,  Ugurel S, Zimmer L,  Banks P,  Spain L, Soon JA,  Enokida T,  Tahara M, Kähler KC,  Seggewiss-Bernhardt R,  Harvey C,  Long GV, Schöberl F,  von Baumgarten L,  Hundsberger T,  Schlaak M, French LE,  Knauss S,  Heinzerling LM.
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.
Data Brief 2022; 45: 108649.
DOI: 10.1016/j.dib.2022.108649

Rosell Diaz A, Lefevre MA,  Mohme S,  Alband N, Nogueira M,  Rodriguez-Lomba E.
Journal Club: Cutaneous squamous cell carcinoma.
Eur J Dermatol 2022; 32(5): 660-662
DOI: 10.1684/ejd.2022.4367

Bernhardt M, Cruz-Garcia Y,  Rech A,  Meierjohann S,  Erhard F, Schilling B,  Schlosser A.
Extending the Mass Spectrometry-Detectable Landscape of MHC Peptides by Use of Restricted Access Material.
Anal Chem 2022; 94(41): 14214-14222
DOI: 10.1021/acs.analchem.2c02198

Zimmermann S,  Aghai F,  Schilling B, Kraus S,  Grigoleit GU,  Kalogirou C, Goebeler ME,  Jung P,  Pelzer T, Klinker H,  Isberner N,  Scherf-Clavel O.
Volumetric absorptive microsampling (VAMS) for the quantification of ten kinase inhibitors and determination of their in vitro VAMS-to-plasma ratio.
J Pharm Biomed Anal 2022; 211: 114623.
DOI: 10.1016/j.jpba.2022.114623.

Steeb T,  Wessely A, Alter M,  Bayerl C,  Bender A, Bruning G,  Dabrowski E,  Debus D, Devereux N,  Dippel E,  Drexler K, Dücker P,  Dummer R,  Emmert S, Elsner P,  Enk A,  Gebhardt C, Gesierich A,  Goebeler M,  Goerdt S, Goetze S,  Gutzmer R,  Haferkamp S, Hansel G,  Hassel JC,  Heinzerling L,  Kähler KC, Kaume KM,  Krapf W,  Kreuzberg N, Lehmann P,  Livingstone E,  Löffler H, Loquai C,  Mauch C,  Mangana J, Meier F,  Meissner M,  Moritz RKC, Maul LV,  Müller V,  Mohr P, Navarini A,  Van Nguyen A,  Pfeiffer C, Pföhler C,  Posch C,  Richtig E, Rompel R,  Sachse MM,  Sauder S, Schadendorf D,  Schatton K,  Schulze HJ, Schultz E,  Schilling B,  Schmuth M, Simon JC,  Streit M,  Terheyden P, Thiem A,  Tüting T,  Welzel J, Weyandt G,  Wesselmann U,  Wollina U, Ziemer M,  Zimmer L,  Zutt M, Berking C,  Schlaak M,  Heppt MV, German Dermatologic Cooperative Oncology Group (DeCOG, committee ocular melanoma).
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG).
J Cancer Res Clin Oncol 2021;147(6):1763-1771
DOI: 10.1007/s00432-020-03450-0

Gangaev A, Rozeman EA,  Rohaan MW,  Isaeva OI, Philips D,  Patiwael S,  van den Berg JH,  Ribas A, Schadendorf D,  Schilling B,  Schumacher TN,  Blank CU, Haanen JBAG,  Kvistborg P.
Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.
Proc Natl Acad Sci U S A 2021;118(43):e2102849118.
DOI: 10.1073/pnas.2102849118

Knispel S, Gassenmaier M,  Menzies AM,  Loquai C, Johnson DB,  Franklin C,  Gutzmer R, Hassel JC,  Weishaupt C,  Eigentler T, Schilling B,  Schummer P,  Sirokay J, Kiecker F,  Owen CN,  Fleischer MI, Cann C,  Kähler KC,  Mohr P, Bluhm L,  Niebel D,  Thoms KM, Goldinger SM,  Reinhardt L,  Meier F, Berking C,  Reinhard R,  Susok L, Ascierto PA,  Drexler K,  Pföhler C, Tietze J,  Heinzerling L,  Livingstone E,  Ugurel S, Long GV,  Stang A,  Schadendorf D,  Zimmer L.
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Eur J Cancer 2021;148:61-75
DOI: 10.1016/j.ejca.2021.01.034

Filipski K,  Scherer M,  Zeiner KN, Bucher A,  Kleemann J,  Jurmeister P, Hartung TI,  Meissner M,  Plate KH, Fenton TR,  Walter J,  Tierling S, Schilling B,  Zeiner PS,  Harter PN.
DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma.
J Immunother Cancer 2021; 9(7):e002226.
DOI: 10.1136/jitc-2020-002226

Zaremba A, Philip M,  Hassel JC,  Glutsch V, Fiocco Z,  Loquai C,  Rafei-Shamsabadi D,  Gutzmer R, Utikal J,  Haferkamp S,  Reinhardt L, Kähler KC,  Weishaupt C,  Moreira A, Thoms KM,  Wilhelm T,  Pföhler C, Roesch A,  Ugurel S,  Zimmer L, Stadtler N,  Sucker A,  Kiecker F, Heinzerling L,  Meier F,  Meiss F, Schlaak M,  Schilling B,  Horn S, Schadendorf D,  Livingstone E.
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.
Eur J Cancer 2021;152:139-154
DOI: 10.1016/j.ejca.2021.04.032

Versluis JM, Reijers ILM,  Rozeman EA,  Menzies AM, van Akkooi ACJ,  Wouters MW,  Ch'ng S, Saw RPM,  Scolyer RA,  van de Wiel BA,  Schilling B, Long GV,  Blank CU.
Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.
Eur J Cancer 2021;148:51-57
DOI: 10.1016/j.ejca.2021.02.012

Lodde G, Forschner A,  Hassel J,  Wulfken LM, Meier F,  Mohr P,  Kaehler K, Schilling B,  Loquai C,  Berking C, Huening S,  Schatton K,  Gebhardt C, Eckardt J,  Gutzmer R,  Reinhardt L, Glutsch V,  Nikfarjam U,  Erdmann M, Stang A,  Kowall B,  Roesch A, Ugurel S,  Zimmer L,  Schadendorf D,  Livingstone E.
Factors Influencing the Adjuvant Therapy Decision: Results of a   Real-World Multicenter Data Analysis of 904 Melanoma Patients.
Cancers (Basel) 2021;13(10):2319.
DOI: 10.3390/cancers13102319

Wessely A, Steeb T,  Berking C,  Schlaak M, Heppt MV,  German Dermatologic Cooperative Oncology Group (DeCOG, committee ocular melanoma). 
Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group.
Eur J Cancer 2021;143:43-45
DOI: 10.1016/j.ejca.2020.10.021

Kähler KC, Gutzmer R,  Meier F,  Zimmer L, Heppt M,  Gesierich A,  Thoms KM, Utikal J,  Hassel JC,  Loquai C, Pföhler C,  Heinzerling L,  Kaatz M, Göppner D,  Pflugfelder A,  Bohne AS, Satzger I,  Reinhardt L,  Placke JM, Schadendorf D,  Ugurel S.
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study.
Front Oncol 2021;11:672172.
DOI: 10.3389/fonc.2021.672172

Kadioglu O, Saeed MEM,  Greten HJ,  Mayr K, Schrama D,  Roos WP,  Efferth T.
Identification of potential inhibitors targeting BRAF-V600E mutant melanoma cells.
J Am Acad Dermatol 2021; 84(4): 1086-1089
DOI: 10.1016/j.jaad.2020.07.069

Koch EAT, Petzold A,  Wessely A,  Dippel E, Gesierich A,  Gutzmer R,  Hassel JC, Haferkamp S,  Hohberger B,  Kähler KC, Knorr H,  Kreuzberg N,  Leiter U, Loquai C,  Meier F,  Meissner M, Mohr P,  Pföhler C,  Rahimi F, Schadendorf D,  Schell B,  Schlaak M, Terheyden P,  Thoms KM,  Schuler-Thurner B,  Ugurel S, Ulrich J,  Utikal J,  Weichenthal M,  Ziller F, Berking C,  Heppt MV,  On Behalf Of The German Dermatologic Cooperative Oncology Group DeCOG Committee Ocular Melanoma.
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis.
Cancers (Basel) 2021;13(13):3359.
DOI: 10.3390/cancers13133359

Fan K,  Spassova I,  Gravemeyer J,  Ritter C, Horny K,  Lange A,  Gambichler T, Ødum N,  Schrama D,  Schadendorf D,  Ugurel S, Becker JC.
Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53.
Oncogene 2021; 40(5): 980-996
DOI: 10.1038/s41388-020-01576-6

Glutsch V, Kneitz H,  Gesierich A,  Goebeler M, Haferkamp S,  Becker JC,  Ugurel S, Schilling B.
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma.
Cancer Immunol Immunother 2021; 70(7): 2087-2093
DOI: 10.1007/s00262-020-02832-0

Stege HM,  Haist M,  Schultheis S,  Fleischer MI, Mohr P,  Ugurel S,  Terheyden P, Thiem A,  Kiecker F,  Leiter U, Becker JC,  Meissner M,  Kleeman J, Pföhler C,  Hassel J,  Grabbe S, Loquai C.
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.
Cancer Immunol Immunother 2021; 70(11): 3313-3322
DOI: 10.1007/s00262-021-02925-4

Hodak E, Sherman S,  Papadavid E,  Bagot M, Querfeld C,  Quaglino P,  Prince HM, Ortiz-Romero PL,  Stadler R,  Knobler R, Guenova E,  Estrach T,  Patsatsi A, Leshem YA,  Prague-Naveh H,  Berti E, Alberti-Violetti S,  Cowan R,  Jonak C, Nikolaou V,  Mitteldorf C,  Akilov O, Geskin L,  Matin R,  Beylot-Barry M,  Vakeva L, Sanches JA,  Servitje O,  Weatherhead S,  Wobser M, Yoo J,  Bayne M,  Bates A, Dunnill G,  Marschalko M,  Buschots AM, Wehkamp U,  Evison F,  Hong E, Amitay-Laish I,  Stranzenbach R,  Vermeer M,  Willemze R, Kempf W,  Cerroni L,  Whittaker S, Kim YH,  Scarisbrick JJ,  Cutaneous Lymphoma International Consortium (CLIC) institutions.
Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study.
Br J Dermatol 2021; 184(3): 524-531
DOI: 10.1111/bjd.19303

Wobser M, Roth S, Appenzeller S, Houben R, Schrama D, Goebeler M, Geissinger E, Rosenwald A, Maurus K.
Targeted Deep Sequencing of Mycosis Fungoides Reveals Intracellular Signaling Pathways Associated with Aggressiveness and Large Cell Transformation.
Cancers (Basel) 2021; 13(21): 5512.
DOI: 10.3390/cancers13215512

Quaglino P, Prince HM,  Cowan R,  Vermeer M, Papadavid E,  Bagot M,  Servitjie O, Berti E,  Guenova E,  Stadler R, Querfeld C,  Busschots AM,  Hodak E, Patsatsi A,  Sanches J,  Maule M, Yoo J,  Kevin M,  Fava P, Ribero S,  Zocchi L,  Rubatto M, Fierro MT,  Wehkamp U,  Marshalko M, Mitteldorf C,  Akilov O,  Ortiz-Romero P,  Estrach T, Vakeva L,  Enz PA,  Wobser M, Bayne M,  Jonak C,  Rubeta M, Forbes A,  Bates A,  Battistella M,  Amel-Kashipaz R,  Vydianath B, Combalia A,  Georgiou E,  Hauben E, Hong EK,  Jost M,  Knobler R, Amitay-Laish I,  Miyashiro D,  Cury-Martins J,  Martinez X, Muniesa C,  Prag-Naveh H,  Stratigos A, Nikolaou V,  Quint K,  Ram-Wolff C, Rieger K,  Stranzenbach R,  Szepesi Á, Alberti-Violetti S,  Felicity E,  Cerroni L,  Kempf W, Whittaker S,  Willemze R,  Kim Y, Scarisbrick JJ.
Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
Br J Dermatol 2021; 184(4): 722-730
DOI: 10.1111/bjd.19252

Kempf W, Mitteldorf C,  Battistella M,  Willemze R, Cerroni L,  Santucci M,  Geissinger E, Jansen P,  Vermeer MH,  Marschalko M, Papadavid E,  Piris MA,  Ortiz-Romero PL,  Novelli M, Paulli M,  Quaglino P,  Ranki A, Rodríguez Peralto JL,  Wobser M,  Auschra B,  Robson A.
Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico-pathological and prognostic features.
J Eur Acad Dermatol Venereol 2021; 35(3): 658-668
DOI: 10.1111/jdv.16969

Wehkamp U,  Mitteldorf C,  Stendel S, Stranzenbach R,  Nicolay JP,  Wobser M, Weichenthal M,  Schneiderbauer R,  Klemke CD,  Hillen U, Kempf W,  Assaf C.
Most rare subtypes of cutaneous lymphoma display variable CD30 expression: analysis of the German Cutaneous Lymphoma Network.
Br J Dermatol 2021; 185(1): 228-230
DOI: 10.1111/bjd.19823

Frings VG,  Roth S,  Rosenwald A,  Goebeler M, Geissinger E,  Wobser M.
EBER in situ hybridization in subcutaneous aluminum granulomas/lymphoid hyperplasia: A diagnostic clue to differentiate injection-associated lymphoid hyperplasia from other forms of pseudolymphomas and cutaneous lymphomas.
J Cutan Pathol 2021; 48(5): 625-631
DOI: 10.1111/cup.13972

Wobser M,  Roth S,  Appenzeller S,  Kneitz H, Goebeler M,  Geissinger E,  Rosenwald A, Maurus K.
Oncogenic Mutations and Gene Fusions in CD30-Positive Lymphoproliferations and Clonally Related Mycosis Fungoides Occurring in the Same Patients.
JID Innov 2021; 1(3): 100034.
DOI: 10.1016/j.xjidi.2021.100034

Dege T,  Wobser M,  Goebeler M, Reichel A.
[Pressure sensitive livid node on the left knee].
Hautarzt 2021; 72(12): 1116-1118
DOI: 10.1007/s00105-021-04827-z

Frings VG, Goebeler M,  Schilling B,  Kneitz H.
Aberrant cytoplasmic connexin43 expression as a helpful marker in vascular neoplasms.
J Cutan Pathol 2021; 48(11): 1335-1341
DOI: 10.1111/cup.14066

Haggenmüller S, Maron RC,  Hekler A,  Utikal JS, Barata C,  Barnhill RL,  Beltraminelli H,  Berking C, Betz-Stablein B,  Blum A,  Braun SA, Carr R,  Combalia M,  Fernandez-Figueras MT,  Ferrara G, Fraitag S,  French LE,  Gellrich FF, Ghoreschi K,  Goebeler M,  Guitera P, Haenssle HA,  Haferkamp S,  Heinzerling L,  Heppt MV, Hilke FJ,  Hobelsberger S,  Krahl D, Kutzner H,  Lallas A,  Liopyris K, Llamas-Velasco M,  Malvehy J,  Meier F, Müller CSL,  Navarini AA,  Navarrete-Dechent C,  Perasole A, Poch G,  Podlipnik S,  Requena L, Rotemberg VM,  Saggini A,  Sangueza OP, Santonja C,  Schadendorf D,  Schilling B, Schlaak M,  Schlager JG,  Sergon M, Sondermann W,  Soyer HP,  Starz H, Stolz W,  Vale E,  Weyers W, Zink A,  Krieghoff-Henning E,  Kather JN, von Kalle C,  Lipka DB,  Fröhling S, Hauschild A,  Kittler H,  Brinker TJ.
Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts.
Eur J Cancer 2021; 156: 202-216
DOI: 10.1016/j.ejca.2021.06.049

Maron RC, Schlager JG,  Haggenmüller S,  von Kalle C, Utikal JS,  Meier F,  Gellrich FF, Hobelsberger S,  Hauschild A,  French L, Heinzerling L,  Schlaak M,  Ghoreschi K, Hilke FJ,  Poch G,  Heppt MV, Berking C,  Haferkamp S,  Sondermann W, Schadendorf D,  Schilling B,  Goebeler M, Krieghoff-Henning E,  Hekler A,  Fröhling S,  Lipka DB, Kather JN,  Brinker TJ.
A benchmark for neural network robustness in skin cancer classification.
Eur J Cancer 2021; 155: 191-199
DOI: 10.1016/j.ejca.2021.06.047

Marquardt A, Solimando AG,  Kerscher A,  Bittrich M, Kalogirou C,  Kübler H,  Rosenwald A, Bargou R,  Kollmannsberger P,  Schilling B, Meierjohann S,  Krebs M.
Subgroup-Independent Mapping of Renal Cell Carcinoma-Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries.
Front Oncol 2021; 11: 621278.
DOI: 10.3389/fonc.2021.621278

Höhn J, Krieghoff-Henning E,  Jutzi TB,  von Kalle C,  Utikal JS, Meier F,  Gellrich FF,  Hobelsberger S,  Hauschild A, Schlager JG,  French L,  Heinzerling L,  Schlaak M, Ghoreschi K,  Hilke FJ,  Poch G, Kutzner H,  Heppt MV,  Haferkamp S, Sondermann W,  Schadendorf D,  Schilling B, Goebeler M,  Hekler A,  Fröhling S, Lipka DB,  Kather JN,  Krahl D, Ferrara G,  Haggenmüller S,  Brinker TJ.
Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification.
Eur J Cancer 2021; 149: 94-101
DOI: 10.1016/j.ejca.2021.02.032

Maron RC, Haggenmüller S,  von Kalle C,  Utikal JS, Meier F,  Gellrich FF,  Hauschild A, French LE,  Schlaak M,  Ghoreschi K, Kutzner H,  Heppt MV,  Haferkamp S, Sondermann W,  Schadendorf D,  Schilling B, Hekler A,  Krieghoff-Henning E,  Kather JN,  Fröhling S, Lipka DB,  Brinker TJ.
Robustness of convolutional neural networks in recognition of pigmented skin lesions.
Eur J Cancer 2021; 145: 81-91
DOI: 10.1016/j.ejca.2020.11.020

Kneitz H,  Goebeler M,  Rütten A 
Nevus Sebaceous of the Scalp With Stepwise Progression Into Invasive Syringocystadenocarcinoma Papilliferum.
Am J Dermatopathol 2021; 43(12): 965-969
DOI: 10.1097/DAD.0000000000002049

Hoesl C,  Fröhlich T,  Posch C, Kneitz H,  Goebeler M,  Schneider MR, Dahlhoff M.
The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.
Mol Oncol 2021; 15(8): 2140-2155
DOI: 10.1002/1878-0261.12945

Höhn J,  Hekler A,  Krieghoff-Henning E,  Kather JN, Utikal JS,  Meier F,  Gellrich FF, Hauschild A,  French L,  Schlager JG, Ghoreschi K,  Wilhelm T,  Kutzner H, Heppt M,  Haferkamp S,  Sondermann W, Schadendorf D,  Schilling B,  Maron RC, Schmitt M,  Jutzi T,  Fröhling S, Lipka DB,  Brinker TJ.
Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review.
J Med Internet Res 2021; 23(7): e20708.
DOI: 10.2196/20708

Kramer R, Zaremba A,  Moreira A,  Ugurel S, Johnson DB,  Hassel JC,  Salzmann M, Gesierich A,  Weppler A,  Spain L, Loquai C,  Dudda M,  Pföhler C, Hepner A,  Long GV,  Menzies AM, Carlino MS,  Sachse MM,  Lebbé C, Baroudjian B,  Enokida T,  Tahara M, Schlaak M,  Hayani K,  Bröckelmann PJ,  Meier F, Reinhardt L,  Friedlander P,  Eigentler T, Kähler KC,  Berking C,  Zimmer L, Heinzerling L.
Hematological immune related adverse events after treatment with immune checkpoint inhibitors.
Eur J Cancer 2021; 147: 170-181
DOI: 10.1016/j.ejca.2021.01.013

Lettau K, Khozooei S,  Kosnopfel C,  Zips D, Schittek B,  Toulany M.
Targeting the Y-box Binding Protein-1 Axis to Overcome Radiochemotherapy   Resistance in Solid Tumors
Int J Radiat Oncol Biol Phys 2021; 111(4): 1072-1087
DOI: 10.1016/j.ijrobp.2021.06.021

Paudel R,  Fusi L,  Schmidt M.
The MEK5/ERK5 Pathway in Health and Disease.
Int J Mol Sci 2021; 22(14): 7594.
DOI: 10.3390/ijms22147594

Zaremba A, Kramer R,  De Temple V,  Bertram S, Salzmann M,  Gesierich A,  Reinhardt L, Baroudjian B,  Sachse MM,  Mechtersheimer G,  Johnson DB, Weppler AM,  Spain L,  Loquai C, Dudda M,  Pföhler C,  Hepner A, Long GV,  Menzies AM,  Carlino MS, Lebbé C,  Enokida T,  Tahara M, Bröckelmann PJ,  Eigentler T,  Kähler KC, Gutzmer R,  Berking C,  Ugurel S, Stadtler N,  Sucker A,  Becker JC, Livingstone E,  Meier F,  Hassel JC, Schadendorf D,  Hanoun M,  Heinzerling L,  Zimmer L.
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis.
Front Oncol 2021; 11: 765608.
DOI: 10.3389/fonc.2021.765608